HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.

Abstract
Multiple autoimmune diseases are characterized by the involvement of autoreactive Abs in pathogenesis. Problems associated with existing therapeutics such as the delivery of intravenous immunoglobulin have led to interest in developing alternative approaches using recombinant or synthetic methods. Toward this aim, in the current study, we demonstrate that the use of Fc-engineered Abs (Abs that enhance IgG degradation [Abdegs]) to block neonatal FcR (FcRn) through high-affinity, Fc region binding is an effective strategy for the treatment of Ab-mediated disease. Specifically, Abdegs can be used at low, single doses to treat disease in the K/B×N serum transfer model of arthritis using BALB/c mice as recipients. Similar therapeutic effects are induced by 25- to 50-fold higher doses of i.v. Ig. Importantly, we show that FcRn blockade is a primary contributing factor toward the observed reduction in disease severity. The levels of albumin, which is also recycled by FcRn, are not affected by Abdeg delivery. Consequently, Abdegs do not alter FcRn expression levels or subcellular trafficking behavior. The engineering of Ab Fc regions to generate potent FcRn blockers therefore holds promise for the therapy of Ab-mediated autoimmunity.
AuthorsDipesh A Patel, Alberto Puig-Canto, Dilip Kumar Challa, Héctor Perez Montoyo, Raimund J Ober, E Sally Ward
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 187 Issue 2 Pg. 1015-22 (Jul 15 2011) ISSN: 1550-6606 [Electronic] United States
PMID21690327 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Blocking
  • Histocompatibility Antigens Class I
  • Immunoglobulin Fc Fragments
  • Immunoglobulin G
  • Receptors, Antigen, T-Cell, alpha-beta
  • Receptors, Fc
  • Recombinant Proteins
  • T cell receptor Vbeta6, human
  • Glucose-6-Phosphate Isomerase
  • Fc receptor, neonatal
Topics
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal (metabolism, therapeutic use)
  • Antibodies, Blocking (genetics, metabolism, therapeutic use)
  • Antibody Affinity (genetics)
  • Arthritis, Experimental (immunology, pathology, therapy)
  • Glucose-6-Phosphate Isomerase (immunology)
  • Histocompatibility Antigens Class I (metabolism)
  • Humans
  • Immunoglobulin Fc Fragments (genetics, metabolism, therapeutic use)
  • Immunoglobulin G (genetics, metabolism, therapeutic use)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred NOD
  • Mice, Transgenic
  • Protein Engineering (methods)
  • Receptors, Antigen, T-Cell, alpha-beta (genetics, immunology, metabolism)
  • Receptors, Fc (antagonists & inhibitors, deficiency, metabolism)
  • Recombinant Proteins (chemical synthesis, metabolism, therapeutic use)
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: